Clinical Trial Update: Tofacitinib in Juvenile Idiopathic Arthritis

View source ↗

Summary

A clinical trial update indicates a study of tofacitinib for juvenile idiopathic arthritis is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf | Conditions: Juvenile Idiopathic Arthritis (JIA) | Status: NOT_YET_RECRUITING